TRANSGENE | 9,49 Euro | +0,06 +0,64 % | |
| WKN: 913048 ISIN: FR0005175080 Ticker-Symbol: TGNA | Frankfurt | 22.05.13 | 15:24 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 21.05. | Transgene Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer | 52 | Business Wire | |
| Regulatory News Transgene SA (Paris:TNG) (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer... Mehr lesen zu: Transgene Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer | ||||
| 21.05. | Transgene Announces its Invesment in ElsaLys Biotech, a New Antibody Company Created by Former Executives | 38 | Business Wire | |
| The Start-up Company Will Develop Therapeutic Antibodies against Novel Targets in the Fields of Cancer and Inflammation Regulatory News: Transgene SA (Euronext Paris: TNG)(Paris:TNG)... Mehr lesen zu: Transgene Announces its Invesment in ElsaLys Biotech, a New Antibody Company Created by Former Executives | ||||
| 17.05. | Transgene Announces its Invesment in ElsaLys Biotech, a New Antibody Company Created by Former Executives | 56 | Business Wire | |
| The Start-up Company Will Develop Therapeutic Antibodies against Novel Targets in the Fields of Cancer and Inflammation Regulatory News: Transgene SA (Euronext Paris: TNG)(Paris:TNG)... Mehr lesen zu: Transgene Announces its Invesment in ElsaLys Biotech, a New Antibody Company Created by Former Executives | ||||
| 17.05. | ElsaLys Biotech, ein neuer Startup-Akteur in der Arena therapeutischer monoklonaler Antikörper, meldet erste Finanzierungsrunde mit Transgene und Sofimac | 77 | Business Wire | |
| ElsaLys Biotech, ein Spinoff-Unternehmen von Transgene R&D, wird neuartige monoklonale Antikörper gegen klassenerste Angriffsziele für die Behandlung von Krebs und Entzündungskrankheiten... Mehr lesen zu: ElsaLys Biotech, ein neuer Startup-Akteur in der Arena therapeutischer monoklonaler Antikörper, meldet erste Finanzierungsrunde mit Transgene und Sofimac | ||||
| 17.05. | The start-up ElsaLys Biotech, a new player in the therapeutic monoclonal antibody arena, announces the first round of financing with Transgene and Sofimac Partners | 63 | Business Wire | |
| Spin-off from Transgene R&D, ElsaLys Biotech will develop novel monoclonal antibodies against first-in-class targets for the treatment of cancer inflammatory diseases. Dr Jean-Yves Bonnefoy... Mehr lesen zu: The start-up ElsaLys Biotech, a new player in the therapeutic monoclonal antibody arena, announces the first round of financing with Transgene and Sofimac Partners | ||||
| 15.05. | Transgene Announces that Clinical Data with Pexa-Vec will be Presented at the 2013 American Society of Clinical Oncology Annual Meeting | 45 | Business Wire | |
| Regulatory News Transgene SA (Paris:TNG) (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer... Mehr lesen zu: Transgene Announces that Clinical Data with Pexa-Vec will be Presented at the 2013 American Society of Clinical Oncology Annual Meeting | ||||
| 29.04. | Transgene: Promising Final Data from the Phase 2 HCVac Trial of TG4040 Presented at EASL 2013 | 39 | Business Wire | |
| Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: FR0005175080), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs... Mehr lesen zu: Transgene: Promising Final Data from the Phase 2 HCVac Trial of TG4040 Presented at EASL 2013 | ||||
| 29.04. | Transgene Presents Promising Pre-Clinical Data on TG1050 to Treat Chronic HBV at EASL 2013 | 45 | Business Wire | |
| Initiation of a Phase I study in 2014 New first in class immunotherapeutic to treat CHB Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: FR0005175080), a ... Mehr lesen zu: Transgene Presents Promising Pre-Clinical Data on TG1050 to Treat Chronic HBV at EASL 2013 | ||||
| 22.04. | Transgene : First Quarter 2013 Financial Report | 26 | Business Wire | |
| Regulatory News Transgene (Paris:TNG) (Euronext Paris: FR0005175080) today issues its quarterly financial report as of March 31, 2013 (first quarter of 2013). Revenue: ... Mehr lesen zu: Transgene : First Quarter 2013 Financial Report | ||||
| 08.04. | Transgene to Present New Data on TG1050 and TG4040 to Treat Chronic Hepatitis B and C at EASL 2013 | 45 | Business Wire | |
| Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: FR0005175080), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs... Mehr lesen zu: Transgene to Present New Data on TG1050 and TG4040 to Treat Chronic Hepatitis B and C at EASL 2013 | ||||
| 28.03. | Sanofi/Transgene Inks Immunotherapy Deal | 7 | Zacks | |
| 26.03. | Sanofi, Transgene partner to develop new platform to produce immunotherapy products | 8 | Pharma Bus Review | |
| 25.03. | Sanofi (SNY), Transgene Enter Long-Term Immunotherapy Development | - | StreetInsider.com | |
| 25.03. | Sanofi and Transgene Announce Long-Term Collaboration | 3 | Benzinga.com | |
| 25.03. | SANOFI: Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy ... | 3 | NYSE Euronext | |
| 25.03. | Sanofi, Transgene Announce Agreement For Creation Of Industrial Platform | 78 | AFX News | |
| PARIS (dpa-AFX) - Sanofi (SNY) and Transgene SA announced a collaboration
agreement for the creation of an industrial platform for the production of
immunotherapy products including Transgene's... Mehr lesen zu: Sanofi, Transgene Announce Agreement For Creation Of Industrial Platform | ||||
| 25.03. | Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments | 100 | Business Wire | |
| - Creation of a new state-of-the-art industrial platform at Genzyme's unit in Lyon - Regulatory News: Sanofi (EURONEXT: SAN and NYSE: SNY) and Transgene SA (Paris:TNG) (NYSE-Euronext:... Mehr lesen zu: Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments | ||||
| 21.03. | Transgene: Annual Results 2012 and Business Update | 44 | Business Wire | |
| Solid operational performance in 2012, in preparation of key
milestones in 2013 with the possible start of two phase 3 clinical
trials for our most advanced products
Cash... Mehr lesen zu: Transgene: Annual Results 2012 and Business Update | ||||
| 01.03. | Transgene to Present at the Cowen & Company 33rd Annual Healthcare Conference | 27 | Business Wire | |
| Regulatory News:
Transgene S.A. (Paris:TNG)(Euronext Paris:FR0005175080) today announced
that Philippe Archinard, Chairman & Chief Executive Officer, will... Mehr lesen zu: Transgene to Present at the Cowen & Company 33rd Annual Healthcare Conference | ||||
| 18.02. | TRANSGENE: CE - Shares - Capital increase | 1 | NYSE Euronext | |
